Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
Mocroft A, Neesgard B, Zangerle R, Rieger A, Castagna A, Spagnuolo V, Antinori A, Lampe FC, Youle M, Vehreschild JJ, Mussini C, Borghi V, Begovac J, Duvivier C, Gunthard HF, Rauch A, Tiraboschi J, Chkhartishvili N, Bolokadze N, Wit F, Wasmuth JC, De Wit S, Necsoi C, Pradier C, Svedhem V, Stephan C, Petoumenos K, Garges H, Rogatto F, Peters L, Ryom L; RESPOND study group. Mocroft A, et al. Among authors: tiraboschi j. HIV Med. 2020 Oct;21(9):599-606. doi: 10.1111/hiv.12888. Epub 2020 Jun 26. HIV Med. 2020. PMID: 32588958 Free article.
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Cain LE, et al. AIDS. 2012 Aug 24;26(13):1691-705. doi: 10.1097/QAD.0b013e328354f497. AIDS. 2012. PMID: 22546987 Free PMC article.
Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
Podzamczer D, Tiraboschi JM, Mallolas J, Curto J, Cárdenes MA, Casas E, Castro A, Echevarría S, Leal M, Lopez Bernaldo de Quirós JC, Moreno S, Puig T, Ribera E, Villalonga C, Gómez-Sirvent JL, García-Henarejos JA, Lopez-Aldeguer J, Barrufet P, Force L, Santos I, Sanz J. Podzamczer D, et al. Among authors: tiraboschi jm. Curr HIV Res. 2012 Sep;10(6):513-20. doi: 10.2174/157016212802429820. Curr HIV Res. 2012. PMID: 22716109 Free article.
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
87 results